Kathmandu, March 12:

Sumy Pharmaceuticals Pvt Ltd (SPPL) launched six oral medicines in the domestic market.

“The company aims in producing parenterals, which have huge demand in the domestic market,” said Purna Bandhan, launching event consultant speaking at a press meet organised in the capital today.

“SPPL boasts latest state-of-the art technology and has the production capacity of 100 kilolitres in 300 working days,” said Sharad Chandra Ojha, national manager, marketing at the Sumy Pharmaceuticals, adding that the pharma production in Nepal in last couple of years has been stagnant and domestic production could meet only about 35 per cent of the demand. “The operation of the new company would decrease the import dependency and also foster good competitiveness,” he claimed.

“Pharma technology is changing rapidly and we need to have a strong and modern infrastructure, if we are to produce quality and quantity medicines. The SPPL is established to fill the dearth of domestic production and is also looking forward expanding its production units in the neighbouring countries,” Ojha said. “Cardiac and neurological injectables are in high demand in the domestic market and the productions of such injectables are in our pipeline.”

The company established with a capital of Rs 280 million aims to produce 100 brands that are consumed in high amount in Nepal.

The 100 brands that the company aims in launching in near future fall in the category of medicines like anti infection, dermatology, general medicine, gastro-enterology, cerebro-cardiovascular and metabolism disorder.

“To sustain in the cut throat competition there should be good management and quality production. We have done vigorous research before launching our products and hope to be able to widen our services in the remotest part of the country,” he said.